Lenstec Rebrands its Newly Approved Multifocal IOL to ClearView 3

Lenstec announced that it has rebranded its new multifocal IOL, the SBL-3, to the ClearView 3 to better describe the vision patients can expect with the new IOL, according to Lenstec. The IOL was approved by the FDA in July 2022. 

"Since approval, the ClearView 3 has been used by many surgeons across the United States. Both surgeon and patient feedback has been exceptional, with early postoperative outcomes meeting or exceeding the performance of previously approved multifocal IOLs," according to Lenstec. "During the FDA trial and early commercial implant experience, the ClearView 3 has proven that its next generation proprietary design lends itself to excellent distance, intermediate, and near visual acuities and a lower rate of dysphotopsias than existing premium IOL implants."